Jami Rubin

Jami Rubin Recent News

This Wasn't A Great ESMO For Bristol-Myers Squibb, But 2017 Could Be A Much Better Year
|
Goldman On The Drug Price Increase Debate: Separating The Winners From The Losers
|
Lilly Is Entering A Period Of Accelerated Growth; Goldman Upgrades Stock To Buy
|
Abbvie Is One Of The Most 'Dislocated Names' In Pharma
|
Greater EpiPen Access, Price Transparency Should Dampen Concern; Goldman Maintains Mylan's Conviction Buy Status
|
Goldman Sachs Talks Pfizer's Acquisition Deal Of Medivation
|
Goldman Sachs Sees 'Limited Upside' In Teva Regardless Of Acquisition Results
|
Goldman Confident In Merck's Keytruda
|
Goldman Removes Mylan From Its Conviction List
|
Allergan Is Primed For Growth, Goldman Sees 27% Upside Potential
|
Goldman Downgrades Zoetis, Sees Limited Upside
|
Bristol-Myers Squibb Target, Estimates Under Review At Goldman Sachs
|
Goldman Selling Perrigo, Prefers Mylan And Teva
|
Goldman Reinstates Coverage On Pfizer And Allergan Following Failed Merger
|
Goldman Upgrades Johnson & Johnson, Removes From America's Sell List
|
Johnson & Johnson Sales Fall: What The Street Is Saying Now
|
UPDATE: Goldman Sachs Upgrades Teva Pharmaceutical Industries
|
UPDATE: Goldman Sachs Downgrades Eli Lilly & Company on Relative Lack of Differentiation in Pipeline
|
UPDATE: Goldman Sachs Upgrades Johnson & Johnson Based on Solid Pharma Business
|
UPDATE: Goldman Sachs Raises PT on Mylan on Increased Confidence in Key Revenue/Earnings Drivers
|
UPDATE: Goldman Sachs Upgrades Perrigo on Multiple Positive Factors
|
UPDATE: Goldman Sachs Downgrades Teva Pharmaceuticals on Brand Focus Taking Time
|
UPDATE: Goldman Sachs Upgrades Forest Laboratories on Increased Potential for Strategic Options
|

Connect With Us

instagramlinkedinyoutube

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2025 Benzinga | All Rights Reserved